$19.62
1.03% yesterday
Nasdaq, Sep 26, 10:00 pm CET
ISIN
US04280A1007
Symbol
ARWR

Arrowhead Pharmaceuticals, Inc. Stock price

$19.62
-5.08 20.57% 1M
-8.22 29.53% 6M
-10.98 35.88% YTD
-6.58 25.11% 1Y
-45.94 70.07% 3Y
-7.65 28.05% 5Y
+4.51 29.85% 10Y
Nasdaq, Closing price Thu, Sep 26 2024
+0.20 1.03%
ISIN
US04280A1007
Symbol
ARWR
Sector
Industry

Key metrics

Market capitalization $2.44b
Enterprise Value $2.46b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 125.44
P/S ratio (TTM) P/S ratio 124.13
P/B ratio (TTM) P/B ratio 7.37
Revenue growth (TTM) Revenue growth -92.33%
Revenue (TTM) Revenue $19.65m
EBIT (operating result TTM) EBIT $-547.21m
Free Cash Flow (TTM) Free Cash Flow $-531.98m
Cash position $436.67m
EPS (TTM) EPS $-4.65
P/E forward negative
P/S forward 39.27
EV/Sales forward 39.69
Short interest 8.54%
Show more

Is Arrowhead Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,900 stocks worldwide.

Arrowhead Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Arrowhead Pharmaceuticals, Inc. forecast:

11x Buy
69%
5x Hold
31%

Analyst Opinions

16 Analysts have issued a Arrowhead Pharmaceuticals, Inc. forecast:

Buy
69%
Hold
31%

Financial data from Arrowhead Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
20 20
92% 92%
100%
- Direct Costs 17 17
54% 54%
89%
2.22 2.22
99% 99%
11%
- Selling and Administrative Expenses 78 78
11% 11%
396%
- Research and Development Expense 454 454
39% 39%
2,312%
-530 -530
213% 213%
-2,696%
- Depreciation and Amortization 17 17
54% 54%
89%
EBIT (Operating Income) EBIT -547 -547
203% 203%
-2,785%
Net Profit -539 -539
197% 197%
-2,741%

In millions USD.

Don't miss a Thing! We will send you all news about Arrowhead Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arrowhead Pharmaceuticals, Inc. Stock News

Neutral
Business Wire
4 days ago
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-INHBE, the company's investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity. Arrowhead also plans to file for regulatory clearance before the end of ...
Positive
Investopedia
24 days ago
Shares of Arrowhead Pharmaceuticals (ARWR) gained Tuesday after the biotech firm announced positive results in a late-stage study of its experimental treatment for a rare metabolic disorder, and said it plans to request regulatory approval to market it.
Neutral
Business Wire
25 days ago
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 3 PALISADE study of investigational plozasiran in patients with familial chylomicronemia syndrome (FCS), a severe and rare genetic disease which currently has no approved treatments in the U.S. PALISADE successfully met its primary endpoint and all multiplicity-cont...
More Arrowhead Pharmaceuticals, Inc. News

Company Profile

Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Head office United States
CEO Christopher Anzalone
Employees 525
Founded 1989
Website www.arrowheadpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today